Dr. Robert Whitfield critiques inflated fat transfer marketing and introduces his Sharp Method, developed through explant surgeries. His research on 694 capsule samples found a 29% contamination rate, informing his approach to safer fat transfer for explant, cancer, and post-mastectomy patients.
Now, most of you watching are probably not your average patients. You may be here because you've heard me speak before, you've done research, you've read potentially one of my books, you've asked questions that doctors couldn't answer or maybe were evasive about. You already know something is off about how fat transfer is marketed. It's very different when you market to the face or the buttocks. You've seen the promises, you've seen results that don't really make sense or match, and you've probably wondered, is it the surgeon or is it something else? And that's the correct instinct. And tonight I'm going to give you the framework to understand exactly what's happening. I built a system on my methodology, the Sharp Method. It started with doing explant surgery and simultaneous fat transfers, which I've done for a long period of time. I published the largest PCR-tested capsule series in the world, 694 consecutive samples, 29% contamination rate. And I can do fat transfers in explant patients and cancer patients and post-mastectomy patients after explant, which I did today, actually. And it's a, it's a system that works for each and every procedure.
